Objective： We investigated the effects of monoclonal antibodies against stathmin 1 combined paclitaxel on the proliferation of HCC cells. Methods： HepG2 cells were treated with monoclonal antibodies against stathmin...Objective： We investigated the effects of monoclonal antibodies against stathmin 1 combined paclitaxel on the proliferation of HCC cells. Methods： HepG2 cells were treated with monoclonal antibodies against stathmin 1, paclitaxel alone or their combination, with the untreated cells used as the control, 24, 48, 72, 96 h later, the cell growth condition was observed by invert microscope and inhabitation rate was studied by MTT assay; The apoptosis was analyzed by flow cytometry with Annexin V/PI. Results： The population decreased and shape, size changed after treating with different concentration of experimental groups. Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both inhibited the proliferation of HepG2 cells, the inhibition ratio of their combination was more higher （P 〈 0.05）, and a synergistic effect of the two agents was noted in their combined action （P 〈 0.05）. Combined treatment of the cells resulted in significantly higher apoptosis rate than that in the other groups （P 〈 0.05）. Conclusion： Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both can inhibit proliferation of HepG2 cells and induce apoptosis. A synergistic effect is obsewed between the monoclonal antibodies against stathmin 1 and paclitaxel in their inhibition of HepG2 cell proliferation.展开更多
目的研究微管解聚蛋白1(Stathmin-1,STMN1)受特化蛋白1(specialized protein 1,SP1)转录调控对子宫平滑肌瘤细胞增殖和凋亡的作用。方法收集2017年6月至2019年6月在南京同仁医院妇产科接受子宫全切除和次全切除的30例子宫肌瘤患者的肌...目的研究微管解聚蛋白1(Stathmin-1,STMN1)受特化蛋白1(specialized protein 1,SP1)转录调控对子宫平滑肌瘤细胞增殖和凋亡的作用。方法收集2017年6月至2019年6月在南京同仁医院妇产科接受子宫全切除和次全切除的30例子宫肌瘤患者的肌瘤组织及周围(瘤旁)平滑肌,RT-qPCR检测子宫平滑肌瘤组织和周围平滑肌组织中STMN1和SP1 mRNA水平。CCK-8、TUNEL和Western blot检测敲低STMN1后人子宫平滑肌瘤(human uterine leiomyoma,HuLM)细胞增殖和凋亡。利用JASPAR网站预测转录因子SP1和STMN1启动子的结合位点。采用RT-qPCR、Western blot、荧光素酶、ChIP验证SP1和STMN1的转录调控,进行功能拯救实验。结果相较于正常平滑肌细胞,子宫平滑肌瘤组织中STMN1和SP1表达上调(P<0.001)。敲低STMN1抑制HuLM细胞增殖并促进凋亡(P<0.001)。SP1作为转录因子正向调控STMN1表达水平,敲低SP1能够抑制HuLM细胞增殖并促进凋亡(P<0.001),进一步过表达STMN1逆转敲低SP1对细胞增殖和凋亡的作用(P<0.001)。结论转录因子SP1通过上调STMN1促进子宫平滑肌瘤细胞增殖并抑制凋亡。展开更多
文摘Objective： We investigated the effects of monoclonal antibodies against stathmin 1 combined paclitaxel on the proliferation of HCC cells. Methods： HepG2 cells were treated with monoclonal antibodies against stathmin 1, paclitaxel alone or their combination, with the untreated cells used as the control, 24, 48, 72, 96 h later, the cell growth condition was observed by invert microscope and inhabitation rate was studied by MTT assay; The apoptosis was analyzed by flow cytometry with Annexin V/PI. Results： The population decreased and shape, size changed after treating with different concentration of experimental groups. Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both inhibited the proliferation of HepG2 cells, the inhibition ratio of their combination was more higher （P 〈 0.05）, and a synergistic effect of the two agents was noted in their combined action （P 〈 0.05）. Combined treatment of the cells resulted in significantly higher apoptosis rate than that in the other groups （P 〈 0.05）. Conclusion： Monoclonal antibodies against stathmin 1 and paclitaxel used alone or in combination both can inhibit proliferation of HepG2 cells and induce apoptosis. A synergistic effect is obsewed between the monoclonal antibodies against stathmin 1 and paclitaxel in their inhibition of HepG2 cell proliferation.
